263 related articles for article (PubMed ID: 9862764)
1. Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB).
Ernsberger P; Ishizuka T; Liu S; Farrell CJ; Bedol D; Koletsky RJ; Friedman JE
J Pharmacol Exp Ther; 1999 Jan; 288(1):139-47. PubMed ID: 9862764
[TBL] [Abstract][Full Text] [Related]
2. Anti-hyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats.
Friedman JE; Ishizuka T; Liu S; Farrell CJ; Koletsky RJ; Bedol D; Ernsberger P
Blood Press Suppl; 1998; 3():32-9. PubMed ID: 10321453
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic actions of an insulin receptor activator and a novel peroxisome proliferator-activated receptor gamma agonist in the spontaneously hypertensive obese rat model of metabolic syndrome X.
Velliquette RA; Friedman JE; Shao J; Zhang BB; Ernsberger P
J Pharmacol Exp Ther; 2005 Jul; 314(1):422-30. PubMed ID: 15833894
[TBL] [Abstract][Full Text] [Related]
4. Reduced insulin receptor signaling in the obese spontaneously hypertensive Koletsky rat.
Friedman JE; Ishizuka T; Liu S; Farrell CJ; Bedol D; Koletsky RJ; Kaung HL; Ernsberger P
Am J Physiol; 1997 Nov; 273(5):E1014-23. PubMed ID: 9374689
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathology in the obese spontaneous hypertensive Koletsky rat: a model of syndrome X.
Ernsberger P; Koletsky RJ; Friedman JE
Ann N Y Acad Sci; 1999 Nov; 892():272-88. PubMed ID: 10842668
[TBL] [Abstract][Full Text] [Related]
6. The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X.
Velliquette RA; Ernsberger P
J Pharmacol Exp Ther; 2003 Aug; 306(2):646-57. PubMed ID: 12756274
[TBL] [Abstract][Full Text] [Related]
7. Contrasting metabolic effects of antihypertensive agents.
Velliquette RA; Ernsberger P
J Pharmacol Exp Ther; 2003 Dec; 307(3):1104-11. PubMed ID: 14557373
[TBL] [Abstract][Full Text] [Related]
8. Sympathetic nervous system in salt-sensitive and obese hypertension: amelioration of multiple abnormalities by a central sympatholytic agent.
Ernsberger P; Koletsky RJ; Collins LA; Bedol D
Cardiovasc Drugs Ther; 1996 Jun; 10 Suppl 1():275-82. PubMed ID: 8827950
[TBL] [Abstract][Full Text] [Related]
9. Pioglitazone improves insulin signaling defects in skeletal muscle from Wistar fatty (fa/fa) rats.
Hayakawa T; Shiraki T; Morimoto T; Shii K; Ikeda H
Biochem Biophys Res Commun; 1996 Jun; 223(2):439-44. PubMed ID: 8670300
[TBL] [Abstract][Full Text] [Related]
10. Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats.
Ding SY; Shen ZF; Chen YT; Sun SJ; Liu Q; Xie MZ
Acta Pharmacol Sin; 2005 May; 26(5):575-80. PubMed ID: 15842776
[TBL] [Abstract][Full Text] [Related]
11. Oxidative stress--mediated alterations in glucose dynamics in a genetic animal model of type II diabetes.
Bitar MS; Al-Saleh E; Al-Mulla F
Life Sci; 2005 Sep; 77(20):2552-73. PubMed ID: 15936776
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of improving effect of losartan on insulin sensitivity of non-insulin-dependent diabetes mellitus rats.
Wu Y; Ouyang JP; Zhou YF; Wu K; Zhao DH; Wen CY
Sheng Li Xue Bao; 2004 Aug; 56(4):539-49. PubMed ID: 15322693
[TBL] [Abstract][Full Text] [Related]
13. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin.
Chazova I; Almazov VA; Shlyakhto E
Diabetes Obes Metab; 2006 Jul; 8(4):456-65. PubMed ID: 16776753
[TBL] [Abstract][Full Text] [Related]
14. Cardiac effects of moxonidine in spontaneously hypertensive obese rats.
Mukaddam-Daher S; Menaouar A; El-Ayoubi R; Gutkowska J; Jankowski M; Velliquette RA; Ernsberger P
Ann N Y Acad Sci; 2003 Dec; 1009():244-50. PubMed ID: 15028594
[TBL] [Abstract][Full Text] [Related]
15. Marked insulin resistance in obese spontaneously hypertensive rat adipocytes is ameliorated by in vivo but not in vitro treatment with moxonidine.
Sun Z; Ernsberger P
J Pharmacol Exp Ther; 2007 Feb; 320(2):845-52. PubMed ID: 17095615
[TBL] [Abstract][Full Text] [Related]
16. Chronic selective glycogen synthase kinase-3 inhibition enhances glucose disposal and muscle insulin action in prediabetic obese Zucker rats.
Dokken BB; Henriksen EJ
Am J Physiol Endocrinol Metab; 2006 Aug; 291(2):E207-13. PubMed ID: 16478771
[TBL] [Abstract][Full Text] [Related]
17. Selective imidazoline agonist moxonidine in obese hypertensive patients.
Sanjuliani AF; de Abreu VG; Francischetti EA
Int J Clin Pract; 2006 May; 60(5):621-9. PubMed ID: 16700870
[TBL] [Abstract][Full Text] [Related]
18. Effect of ginsam, a vinegar extract from Panax ginseng, on body weight and glucose homeostasis in an obese insulin-resistant rat model.
Lim S; Yoon JW; Choi SH; Cho BJ; Kim JT; Chang HS; Park HS; Park KS; Lee HK; Kim YB; Jang HC
Metabolism; 2009 Jan; 58(1):8-15. PubMed ID: 19059525
[TBL] [Abstract][Full Text] [Related]
19. N-3 polyunsaturated fatty acids prevent the defect of insulin receptor signaling in muscle.
Taouis M; Dagou C; Ster C; Durand G; Pinault M; Delarue J
Am J Physiol Endocrinol Metab; 2002 Mar; 282(3):E664-71. PubMed ID: 11832371
[TBL] [Abstract][Full Text] [Related]
20. Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats.
Zhao M; Li Y; Wang J; Ebihara K; Rong X; Hosoda K; Tomita T; Nakao K
Diabetes Obes Metab; 2011 Dec; 13(12):1123-9. PubMed ID: 21749604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
